Nurix Therapeutics (NRIX) Current Deferred Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Current Deferred Revenue data on file, last reported at $18.8 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $18.8 million, down 38.69% year-over-year; the trailing twelve-month figure through Feb 2026 was $18.8 million (down 38.69% YoY), and the FY2025 annual result was $17.6 million, down 54.18% from the prior year.
• Current Deferred Revenue advanced to $18.8 million in Q1 2026 per NRIX's latest filing, from $17.6 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $48.1 million in Q4 2023 and troughed at $17.6 million in Q4 2025.
• A 5-year average of $36.5 million and a median of $38.3 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue surged 49.82% in 2024, then plunged 54.18% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $37.6 million in 2022, then advanced by 27.81% to $48.1 million in 2023, then declined by 20.24% to $38.4 million in 2024, then sank by 54.18% to $17.6 million in 2025, then grew by 6.68% to $18.8 million in 2026.
• Business Quant data shows NRIX's Current Deferred Revenue at $18.8 million in Q1 2026, $17.6 million in Q4 2025, and $26.0 million in Q3 2025.